Bowen Hanes & Co. Inc. lessened its stake in Thermo Fisher Scientific Inc (NYSE:TMO) by 2.1% in the second quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission. The fund owned 212,848 shares of the medical research company’s stock after selling 4,483 shares during the period. Thermo Fisher Scientific comprises about 1.8% of Bowen Hanes & Co. Inc.’s holdings, making the stock its 10th largest holding. Bowen Hanes & Co. Inc. owned approximately 0.05% of Thermo Fisher Scientific worth $37,136,000 as of its most recent filing with the Securities and Exchange Commission.

Other hedge funds and other institutional investors also recently added to or reduced their stakes in the company. Proficio Capital Partners LLC lifted its stake in shares of Thermo Fisher Scientific by 71.5% in the 1st quarter. Proficio Capital Partners LLC now owns 607 shares of the medical research company’s stock valued at $105,000 after acquiring an additional 253 shares during the last quarter. Chicago Partners Investment Group LLC bought a new stake in shares of Thermo Fisher Scientific in the 2nd quarter valued at about $108,000. Cribstone Capital Management LLC lifted its stake in shares of Thermo Fisher Scientific by 8.7% in the 2nd quarter. Cribstone Capital Management LLC now owns 625 shares of the medical research company’s stock valued at $109,000 after acquiring an additional 50 shares during the last quarter. Sharkey Howes & Javer lifted its stake in shares of Thermo Fisher Scientific by 1.0% in the 1st quarter. Sharkey Howes & Javer now owns 733 shares of the medical research company’s stock valued at $113,000 after acquiring an additional 7 shares during the last quarter. Finally, CWM LLC lifted its stake in shares of Thermo Fisher Scientific by 17.0% in the 2nd quarter. CWM LLC now owns 710 shares of the medical research company’s stock valued at $124,000 after acquiring an additional 103 shares during the last quarter. 83.52% of the stock is owned by institutional investors.

Thermo Fisher Scientific Inc (NYSE:TMO) opened at 191.66 on Friday. Thermo Fisher Scientific Inc has a 12-month low of $139.07 and a 12-month high of $194.30. The stock has a market cap of $74.77 billion, a P/E ratio of 33.39 and a beta of 1.05. The firm’s 50 day moving average price is $179.77 and its 200-day moving average price is $170.30.

Thermo Fisher Scientific (NYSE:TMO) last announced its quarterly earnings data on Wednesday, July 26th. The medical research company reported $2.30 earnings per share (EPS) for the quarter, topping the Thomson Reuters’ consensus estimate of $2.27 by $0.03. The business had revenue of $5 billion during the quarter, compared to the consensus estimate of $4.92 billion. Thermo Fisher Scientific had a net margin of 11.80% and a return on equity of 15.97%. The firm’s quarterly revenue was up 10.2% compared to the same quarter last year. During the same quarter last year, the firm earned $2.03 earnings per share. Equities research analysts anticipate that Thermo Fisher Scientific Inc will post $9.34 earnings per share for the current fiscal year.

The company also recently disclosed a quarterly dividend, which will be paid on Monday, October 16th. Shareholders of record on Friday, September 15th will be paid a $0.15 dividend. This represents a $0.60 annualized dividend and a yield of 0.31%. The ex-dividend date of this dividend is Thursday, September 14th. Thermo Fisher Scientific’s payout ratio is currently 10.45%.

In other news, Director Jim P. Manzi sold 1,000 shares of Thermo Fisher Scientific stock in a transaction that occurred on Thursday, August 17th. The shares were sold at an average price of $175.20, for a total transaction of $175,200.00. Following the completion of the sale, the director now owns 38,757 shares of the company’s stock, valued at $6,790,226.40. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is accessible through this hyperlink. Also, Director C Martin Harris sold 360 shares of Thermo Fisher Scientific stock in a transaction that occurred on Wednesday, August 30th. The shares were sold at an average price of $180.97, for a total transaction of $65,149.20. Following the sale, the director now directly owns 5,312 shares of the company’s stock, valued at approximately $961,312.64. The disclosure for this sale can be found here. In the last three months, insiders sold 22,738 shares of company stock valued at $4,021,512. 0.49% of the stock is owned by insiders.

A number of research firms have recently weighed in on TMO. Zacks Investment Research lowered Thermo Fisher Scientific from a “buy” rating to a “hold” rating in a research note on Tuesday. Cowen and Company reissued an “outperform” rating and issued a $220.00 target price (up previously from $200.00) on shares of Thermo Fisher Scientific in a research note on Sunday, September 10th. Morgan Stanley reissued an “overweight” rating and issued a $220.00 target price on shares of Thermo Fisher Scientific in a research note on Wednesday, September 6th. Bank of America Corporation reissued a “buy” rating and issued a $210.00 target price (up previously from $200.00) on shares of Thermo Fisher Scientific in a research note on Friday, July 21st. Finally, Barclays PLC reissued an “overweight” rating and issued a $200.00 target price (up previously from $190.00) on shares of Thermo Fisher Scientific in a research note on Monday, July 17th. One analyst has rated the stock with a hold rating, seventeen have given a buy rating and one has assigned a strong buy rating to the company’s stock. The company presently has an average rating of “Buy” and a consensus price target of $193.56.

ILLEGAL ACTIVITY NOTICE: This article was originally published by Daily Political and is the property of of Daily Political. If you are reading this article on another site, it was illegally stolen and republished in violation of U.S. and international trademark & copyright law. The legal version of this article can be viewed at https://www.dailypolitical.com/2017/09/15/bowen-hanes-co-inc-has-37-14-million-stake-in-thermo-fisher-scientific-inc-tmo.html.

About Thermo Fisher Scientific

Thermo Fisher Scientific Inc develops, manufactures and sells a range of products. The Company provides analytical instruments, equipment, reagents and consumables, software and services for research, manufacturing, analysis, discovery and diagnostics. It operates through four segments: Life Sciences Solutions, Analytical Instruments, Specialty Diagnostics, and Laboratory Products and Services.

Want to see what other hedge funds are holding TMO? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Thermo Fisher Scientific Inc (NYSE:TMO).

Institutional Ownership by Quarter for Thermo Fisher Scientific (NYSE:TMO)

Receive News & Ratings for Thermo Fisher Scientific Inc Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Thermo Fisher Scientific Inc and related companies with MarketBeat.com's FREE daily email newsletter.